Figure 4.
Asciminib reduces the leukemic burden and improves survival outcomes in vivo. NSG (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ) mice injected with patient cells that harbored the ZC3HAV1::ABL2 fusion gene were treated with vehicle control (blue curves) or asciminib (red curves). (A) The leukemic burden was evaluated by tracking hCD45+ cells in the peripheral blood. Each line represents an individual mouse. The treatment window is depicted in grey. (B) Kaplan-Meier curves of the control mice (n = 7) and asciminib-treated mice (n = 8) (30 mg/kg per day). ∗∗∗P = .0003. Statistical significance was measured using the log-rank test. (C) Spleen and (D) liver weights from the control and asciminib-treated mice at the experimental end point. Student t tests were used to determine significance. ∗P < .05; ∗∗∗P < .001. (E) Representative hematoxylin and eosin stains of BM, spleen, and liver sections. Images were analyzed using CaseViewer Software (version 2.2 RTM).

Asciminib reduces the leukemic burden and improves survival outcomes in vivo. NSG (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ) mice injected with patient cells that harbored the ZC3HAV1::ABL2 fusion gene were treated with vehicle control (blue curves) or asciminib (red curves). (A) The leukemic burden was evaluated by tracking hCD45+ cells in the peripheral blood. Each line represents an individual mouse. The treatment window is depicted in grey. (B) Kaplan-Meier curves of the control mice (n = 7) and asciminib-treated mice (n = 8) (30 mg/kg per day). ∗∗∗P = .0003. Statistical significance was measured using the log-rank test. (C) Spleen and (D) liver weights from the control and asciminib-treated mice at the experimental end point. Student t tests were used to determine significance. ∗P < .05; ∗∗∗P < .001. (E) Representative hematoxylin and eosin stains of BM, spleen, and liver sections. Images were analyzed using CaseViewer Software (version 2.2 RTM).

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal